Horizon Pharma Plc (HZNP)

19.07
NASDAQ : Health Technology
Prev Close 19.09
Day Low/High 19.00 / 19.57
52 Wk Low/High 12.55 / 21.25
Avg Volume 1.23M
Exchange NASDAQ
Shares Outstanding 166.63M
Market Cap 3.18B
EPS -2.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Horizon Pharma Plc Announces Presentation Of Data From 48 Week Off-Therapy Follow-Up To The Phase 2 Trial Of Teprotumumab

Horizon Pharma Plc Announces Presentation Of Data From 48 Week Off-Therapy Follow-Up To The Phase 2 Trial Of Teprotumumab

Horizon Pharma plc (NASDAQ:HZNP) announced new data from the Phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) showing a majority of patients that had reductions in proptosis at week 24...

Http://www.naprtcs.org

Http://www.naprtcs.org

A prospective longitudinal natural history registry designed to provide long-term data evaluating people living with cystinosis was launched today at a meeting of The North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) in Chicago,...

Horizon Pharma Plc Initiates Clinical Trial To Evaluate KRYSTEXXA® (pegloticase Injection) With Methotrexate To Enhance Response Rates For People Living With Uncontrolled Gout

Horizon Pharma Plc Initiates Clinical Trial To Evaluate KRYSTEXXA® (pegloticase Injection) With Methotrexate To Enhance Response Rates For People Living With Uncontrolled Gout

Horizon Pharma plc (Nasdaq: HZNP) enrolled the first patient in a clinical trial evaluating the use of KRYSTEXXA® (pegloticase injection) with methotrexate to sustain lower serum uric acid (sUA) levels of people living with chronic gout refractory to...

Horizon Pharma Plc To Present 48-Week Follow-Up Analysis Of The Teprotumumab Phase 2 Trial At The Annual Meeting Of The American Thyroid Association

Horizon Pharma Plc To Present 48-Week Follow-Up Analysis Of The Teprotumumab Phase 2 Trial At The Annual Meeting Of The American Thyroid Association

Horizon Pharma plc (NASDAQ: HZNP) will present new data on the 48-week follow up for the Phase 2 clinical trial evaluating teprotumumab for the treatment of moderate-to-severe active thyroid eye disease (TED).

Horizon Pharma Plc To Participate In The Morgan Stanley 16th Annual Global Healthcare Conference

Horizon Pharma Plc To Participate In The Morgan Stanley 16th Annual Global Healthcare Conference

Horizon Pharma plc (Nasdaq: HZNP) announced today that the company will participate in the following conference: Morgan Stanley 16 th Annual Global Healthcare Conference Date: Sept.

Horizon Pharma Plc Completes Enrollment Of Confirmatory Phase 3 Trial Of Teprotumumab Ahead Of Schedule

Horizon Pharma Plc Completes Enrollment Of Confirmatory Phase 3 Trial Of Teprotumumab Ahead Of Schedule

Horizon Pharma plc (NASDAQ:HZNP) announced the early completion of enrollment for the confirmatory Phase 3 trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED).

PEOPLE And Great Place To Work® Name Horizon Pharma Plc To 2018 "50 Companies That Care" List

PEOPLE And Great Place To Work® Name Horizon Pharma Plc To 2018 "50 Companies That Care" List

Horizon Pharma plc (Nasdaq: HZNP) today announced that the company has been named to PEOPLE's "50 Companies That Care " list for 2018.

Horizon Pharma Plc Announces The U.S. Patent And Trademark Office Issuance Of Additional Notices Of Allowance With Claims Covering RAVICTI® (glycerol Phenylbutyrate) Oral Liquid

Horizon Pharma Plc Announces The U.S. Patent And Trademark Office Issuance Of Additional Notices Of Allowance With Claims Covering RAVICTI® (glycerol Phenylbutyrate) Oral Liquid

Horizon Pharma plc (Nasdaq: HZNP) today announced that it has received two Notices of Allowance from the United States Patent and Trademark Office for U.

Horizon Pharma Plc To Release Second-Quarter 2018 Financial Results and Host Webcast On August 8, 2018

Horizon Pharma Plc To Release Second-Quarter 2018 Financial Results and Host Webcast On August 8, 2018

Horizon Pharma plc (Nasdaq: HZNP) announced today that its second-quarter financial results will be released on Wednesday, August 8, 2018.

VMware and Chevron Are Among 11 Well-Known Stocks Ready to Change Direction

VMware and Chevron Are Among 11 Well-Known Stocks Ready to Change Direction

These names are showing bullish and bearish technical patterns over the past week.

Horizon Pharma Gift Establishes First Clinical Team Endowment At Children's National Rare Disease Institute

Horizon Pharma Gift Establishes First Clinical Team Endowment At Children's National Rare Disease Institute

The endowment will support a clinical care team dedicated to providing rare disease patients with earlier intervention and more consistent treatment over the course of their lifetimes

First Week of HZNP May 18th Options Trading

First Week of HZNP May 18th Options Trading

Investors in Horizon Pharma plc saw new options begin trading this week, for the May 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 98 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Horizon Pharma Plc Announces Agreement To License Pre-Clinical Uricase Derivative (MEDI4945) From MedImmune

Horizon Pharma Plc Announces Agreement To License Pre-Clinical Uricase Derivative (MEDI4945) From MedImmune

Agreement Aims to Further Expand Growing Gout Franchise 

TheStreet Quant Rating: D+ (Sell)